{"id":"NCT02085135","sponsor":"Alkermes, Inc.","briefTitle":"A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)","officialTitle":"A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2014-03-12","resultsPosted":"2019-03-27","lastUpdate":"2019-08-14"},"enrollment":66,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"ALKS 5461","otherNames":[]}],"arms":[{"label":"Titration Schedule 1","type":"EXPERIMENTAL"},{"label":"Titration Schedule 2","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.","primaryOutcome":{"measure":"Number of Subjects With Adverse Events (AEs)","timeFrame":"8 weeks","effectByArm":[{"arm":"1-Week Titration","deltaMin":27,"sd":null},{"arm":"2-Week Titration","deltaMin":28,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":9,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":["Constipation","Nausea","Dry Mouth","Headache","Vomiting"]}}